Idiopathic hyperammonemia after chemotherapy with vinorelbine, topotecan, and cisplatin in a patient with acute lymphocytic leukemia

Yu Hsien Chen, Tzeon Jye Chiou, Yen Ning Hsu, Chun Yu Liu

Research output: Contribution to journalArticlepeer-review

7 Citations (Scopus)

Abstract

Idiopathic hyperammonemia (IHA) had been reported in some patients with hematological malignancy after receiving intensive chemotherapy, following bone marrow transplantation, or after using 5-fluoro-uracil for some solid tumors. The chemotherapeutic agents involved include cytarabine, daunomycin, cyclophosphamide, vincristine, amsacrine, etoposide, asparaginase, busulfan, and methotraxate, all used for treating hematological malignancies. No previous reports have described the association between idiopathic hyperammonemia and combined chemotherapy with vinorelbine, topotecan, and cisplatin. We describe a 20-year-old girl with normal liver function and relapsed precursor B-lymphoblastic leuke-mia receiving the modified TVTG (topotecan, vinorelbine, thiotepa, dexamethasone, and gemcitabine) protocol to control her disease. We used cisplatin (30 mg/m2/day) to replace thiotepa on day 3 because thiotepa was not available in Taiwan. The patient developed acute idiopathic hyperammonemia after 5 days of chemotherapy and died 9 days after chemotherapy. To our knowledge, this patient is the first re-port of the association of hyperammonemia and chemotherapy with vinorelbine, topotecan, and cisplatin in the English literature.

Original languageEnglish
Pages (from-to)199-202
Number of pages4
JournalHematology/ Oncology and Stem Cell Therapy
Volume3
Issue number4
DOIs
Publication statusPublished - 2010
Externally publishedYes

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Idiopathic hyperammonemia after chemotherapy with vinorelbine, topotecan, and cisplatin in a patient with acute lymphocytic leukemia'. Together they form a unique fingerprint.

Cite this